Start here if you're new
what it is
Oramed is trying to turn injected diabetes drugs into pills, starting with oral insulin and oral GLP-1.
how it gets paid
Last year Oramed Pharma made $1M in revenue. other reported revenue was the main engine at $2M, or 100% of sales.
what just happened
Revenue was $2M, while EPS hit $1.26 on a business with just 0.7% gross margin.
At a glance
C++ balance sheet — some cracks in the foundation
20/100 earnings predictability — expect surprises
3.3x trailing p/e — the market's not buying it — or you found a deal
3.1% return on capital — nothing to write home about
-$0.48 fy2024 eps est
xvary composite: 40/100 — below average
What they do
Oramed is trying to turn injected diabetes drugs into pills, starting with oral insulin and oral GLP-1.
You are betting on convenience: a capsule instead of an injection. Oramed's edge is its oral delivery platform, and it kept long-term debt at just $1M, or 0% of capital, while advancing that idea. The moat is the drug-delivery know-how, not today's sales.
How they make money
$1M
annual revenue
other reported revenue
$2M
+100%
ormd-0801 oral insulin
$0M
flat at $0
ormd-0901 oral glp-1
$0M
flat at $0
oral leptin capsule
$0M
flat at $0
The products that matter
balance sheet asset base
Cash and equivalents
$65M · 47% of market value
this is the asset that matters. $65M in cash against a $137M market cap is the reason the stock still has optionality despite only about $1M in annual revenue.
downside support
sold development asset
ORMD-0801 sale economics
jan 2026 sale · $65M gain
the oral insulin program was the old story. selling it created the $65M pre-tax gain reported for the nine months ended Sept 30, 2025, but it also removed the company's central operating thesis.
former flagship
Key numbers
3.3x
trailing p/e
P/E → stock price divided by reported profit → so what: it looks cheap until you notice fiscal 2024 EPS was still -$0.48.
-$0.48
fy2024 eps
EPS → profit per share → so what: last fiscal year ended in a loss, even after fiscal 2023 showed a positive $0.14.
3.1%
return on capital
Return on capital → profit earned on money put into the business → so what: the current operating machine is barely producing returns.
$1M
long-term debt
Long-term debt → money owed beyond one year → so what: the balance sheet is light, which buys time for a pre-revenue biotech.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $1M (0% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for ORMP right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Revenue was $2M, while EPS hit $1.26 on a business with just 0.7% gross margin.
Gross margin → sales left after direct costs → so what: only 0.7 cents of each revenue dollar stayed gross. Quarterly EPS has been lumpy, moving from $0.22 to -$0.48 to -$0.26 across fiscal 2024.
$2M
revenue
$1.26
eps
0.7%
gross margin
the number that mattered
Gross margin was 0.7%, which tells you the current revenue base is too small to matter without a real product launch.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is post-sale capital misallocation after the ORMD-0801 divestiture.
med
No operating engine left
You now own a company with about $1M in annual revenue after it sold the pipeline that defined it. That means the market has very little operating data to anchor on.
If management does not replace the lost development story with a credible new asset or business line, the stock can keep trading like a discounted cash shell instead of a biotech.
med
Cash can disappear two ways
The company has $65M in cash, but it has already declared a $0.25 special dividend and spent $361K on buybacks in Q3 2026. Capital returns are shareholder-friendly until they compete with the need for a new strategy.
A few quarters of poorly justified distributions, acquisitions, or internal spending would weaken the 47%-of-market-cap cash support that makes the stock interesting.
med
Remaining upside is indirect
The sold oral insulin program can still influence sentiment through Lifeward trial progress, but Oramed no longer controls the central asset the way it once did. You're further from the science and closer to transaction economics.
Positive data could help the narrative. Negative data would remove one of the few reasons investors might still treat this like a pipeline story.
These risks all connect back to the same math: about $1M in revenue, $65M in cash, and a $137M market cap. The spread between those numbers is the opportunity and the danger.
source: institutional data · regulatory filings · risk analysis
Pay attention to
cash
Whether the $65M cushion holds
Cash is 47% of market value today. If that balance starts shrinking without a clearly better asset replacing it, the entire special-situation case weakens fast.
catalyst
Any deal that defines the next company
Acquisition, merger, licensing transaction, or new pipeline bet — whatever comes next will matter more than the current revenue base because there barely is one.
capital returns
More dividends or repurchases
The $0.25 special dividend and $361K in buybacks show one path for the cash. Good if shares are cheap. Bad if the company is quietly liquidating without saying so.
legacy asset
Lifeward trial progress on the sold program
The old oral insulin asset is no longer the core business, but it still affects sentiment. If that story fades, investors are left staring directly at the cash pile and little else.
Analyst rankings
earnings predictability
20 / 100
Earnings are hard to model because the recent profit swing came from a sale, not an operating trend. In human-speak, this stock can look cheap one quarter and empty the next.
risk rank
3
Safer than 50% of stocks on the balance-sheet score, largely because debt is only $1M. That does not make the business model safe.
source: institutional data
Institutional activity
institutional ownership data for ORMP is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive